City Therapeutics Inc.
CTY
NASDAQ21.46
USD
-0.94
- -
ISIN
US1787821081
CUSIP
178782108
Return %
Stock
S&P500
1Y
-5.55
14.20
3Y
-5.55
82.01
5Y
-5.55
69.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Cambridge MA United States of America
- IPO Date
- Oct 16, 2026
- Website
- citytx.com
- Similar Companies
- Business
- City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
Company News
U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings
City Therapeutics Announces Pricing of Upsized Initial Public Offering
City Therapeutics eyes valuation of up to $956.3 million in US IPO amid biotech listing push
City Therapeutics, RNAi Treatment Developer, Files For IPO
Baby Bonds Complete Review